Pharmagen, Inc. (PHRX)
- Previous Close
0.0000 - Open
0.0000 - Bid --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 0.0001 - Volume
750 - Avg. Volume
0 - Market Cap (intraday)
3,619 - Beta (5Y Monthly) -0.43
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Pharmagen, Inc. distributes specialty drugs to hospitals, acute care facilities, surgery centers, and other healthcare practitioners in the United States. The company sources and distributes specialty drugs, blood plasma derivatives, specialty products, vaccines, anti-infectives, and hard-to-find pharmaceuticals. It offers plasma derivatives for treating serious medical conditions, such as cancer, hemophilia, rheumatoid arthritis, multiple scleroses, blood disorders, hepatitis, and HIV; and specialty products for treating respiratory, oncology, cardiovascular, and hormonal syndromes. The company also manufactures and distributes health supplements, including Clotamin, a specialized over-the-counter multivitamin dietary supplement for patients on Warfarin. In addition, it sells traditional pharmaceuticals to its distribution customers, such as antibiotics, vaccines, and other oral and injectable pharmaceuticals; and specializes in the formulation of drugs. The company was formerly known as Sunpeaks Ventures, Inc. and changed its name to Pharmagen, Inc. in January 2013. Pharmagen, Inc. is based in Silver Spring, Maryland.
www.pharmageninc.comRelated News
Performance Overview: PHRX
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PHRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PHRX
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
1.35
Enterprise Value/EBITDA
-2.16
Financial Highlights
Profitability and Income Statement
Profit Margin
-133.10%
Return on Assets (ttm)
-58.91%
Return on Equity (ttm)
--
Revenue (ttm)
4.41M
Net Income Avi to Common (ttm)
-6.43M
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
264.67k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
4.41M
Company Insights: PHRX
PHRX does not have Company Insights